[
  {
    "ts": null,
    "headline": "UBS Reaffirms Buy on Elevance Despite Adjusted 2025 Earnings Outlook",
    "summary": "Elevance Health, Inc. (NYSE:ELV) ranks among the best fundamental stocks to buy according to hedge funds. On June 17, UBS reaffirmed its Buy rating and $555 price target for Elevance Health, Inc. (NYSE:ELV), even after the company modified its 2025 earnings distribution. Elevance Health, Inc. (NYSE:ELV) originally predicted that first-half earnings would account for 62–63% […]",
    "url": "https://finnhub.io/api/news?id=bc9cf956c63388cf61fa4b2403d479693fbcbab5cc65338236bbdfab78b15881",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751216013,
      "headline": "UBS Reaffirms Buy on Elevance Despite Adjusted 2025 Earnings Outlook",
      "id": 135633217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "Elevance Health, Inc. (NYSE:ELV) ranks among the best fundamental stocks to buy according to hedge funds. On June 17, UBS reaffirmed its Buy rating and $555 price target for Elevance Health, Inc. (NYSE:ELV), even after the company modified its 2025 earnings distribution. Elevance Health, Inc. (NYSE:ELV) originally predicted that first-half earnings would account for 62–63% […]",
      "url": "https://finnhub.io/api/news?id=bc9cf956c63388cf61fa4b2403d479693fbcbab5cc65338236bbdfab78b15881"
    }
  }
]